Survey of Maribavir Tablets for Treating Cytomegalovirus Infection in Organ Transplant Patients in Japan

What this Trial Is About

Researchers are evaluating Maribavir tablets for participants in Japan who have Cytomegalovirus CMV infection that does not respond to existing anti-CMV treatments, especially after organ transplantation including hematopoietic stem cell transplantation. The study aims to see if Maribavir can protect against CMV infection and to monitor any side effects during treatment. The sponsor, Takeda, provides instructions but does not influence treatment decisions. Participants will take Maribavir tablets orally at a dose of 400 milligrams twice a day, following their clinics usual practice. The study does not control how treatment is given but collects information on how participants respond to Maribavir over a period of 27 weeks. This period allows researchers to observe the treatments effects and any adverse reactions. During the 27 weeks, study doctors will monitor participants closely for side effects and record safety data. They will also measure how the CMV infection responds to treatment, including viral clearance, resistance to Maribavir, graft rejection, graft-versus-host disease, and mortality rates. This observational study helps gather important information about Maribavirs impact on patients with difficult-to-treat CMV infection.

A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection